JP2009512705A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009512705A5 JP2009512705A5 JP2008536749A JP2008536749A JP2009512705A5 JP 2009512705 A5 JP2009512705 A5 JP 2009512705A5 JP 2008536749 A JP2008536749 A JP 2008536749A JP 2008536749 A JP2008536749 A JP 2008536749A JP 2009512705 A5 JP2009512705 A5 JP 2009512705A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- solvate
- ester
- acceptable salt
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 7
- 150000002148 esters Chemical class 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- 210000000941 bile Anatomy 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
- 239000000843 powder Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- -1 cachets Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003067 chemokine receptor CCR5 antagonist Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/255,643 US7825121B2 (en) | 1999-05-04 | 2005-10-21 | Piperazine derivatives useful as CCR5 antagonists |
| PCT/US2006/040636 WO2007050375A2 (en) | 2005-10-21 | 2006-10-18 | Piperazine derivatives useful as ccr5 antagonists |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012007201A Division JP2012072195A (ja) | 2005-10-21 | 2012-01-17 | Ｃｃｒ５アンタゴニストとして有用なピペラジン誘導体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009512705A JP2009512705A (ja) | 2009-03-26 |
| JP2009512705A5 true JP2009512705A5 (https=) | 2012-03-22 |
Family
ID=37872167
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008536749A Pending JP2009512705A (ja) | 2005-10-21 | 2006-10-18 | Ｃｃｒ５アンタゴニストとして有用なピペラジン誘導体 |
| JP2012007201A Pending JP2012072195A (ja) | 2005-10-21 | 2012-01-17 | Ｃｃｒ５アンタゴニストとして有用なピペラジン誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012007201A Pending JP2012072195A (ja) | 2005-10-21 | 2012-01-17 | Ｃｃｒ５アンタゴニストとして有用なピペラジン誘導体 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US7825121B2 (https=) |
| EP (1) | EP1951708B1 (https=) |
| JP (2) | JP2009512705A (https=) |
| KR (1) | KR20080058486A (https=) |
| CN (1) | CN101326178A (https=) |
| AR (1) | AR058105A1 (https=) |
| AU (1) | AU2006306491B2 (https=) |
| BR (1) | BRPI0617731A2 (https=) |
| CA (1) | CA2626565A1 (https=) |
| EC (1) | ECSP088378A (https=) |
| IL (1) | IL190902A0 (https=) |
| NO (1) | NO20082297L (https=) |
| PE (1) | PE20070711A1 (https=) |
| RU (1) | RU2008119652A (https=) |
| TW (1) | TW200800234A (https=) |
| WO (1) | WO2007050375A2 (https=) |
| ZA (1) | ZA200803454B (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0509803A (pt) | 2004-04-13 | 2007-09-18 | Incyte Corp | derivados de piperazinilpiperidina como antagonistas de receptor de quimiocina |
| KR20080064173A (ko) * | 2005-10-21 | 2008-07-08 | 글락소 그룹 리미티드 | 항균제로서 유용한 페리 축합 트리시클릭 화합물 |
| US20080108586A1 (en) * | 2006-09-06 | 2008-05-08 | Incyte Corporation | Combination therapy for human immunodeficiency virus infection |
| WO2010081851A1 (en) | 2009-01-14 | 2010-07-22 | Genoscience Pharma | Piperidin-4-ylpiperazine compounds for the treatment of hcv infection |
| BR112013023050A8 (pt) | 2011-03-09 | 2018-09-25 | G Pestell Richard | antagonista de ccr5, método para determinar se um indivíduo humano tendo câncer de próstata está sofrendo de ou sob o risco de desenvolver metástase, para identificar um antagonista de ccr5, método para determinar se um indivíduo humano tendo câncer de próstata está sofrendo de ou sob o risco de desenvolver metástase, para identificar um composto candidato, para produzir in vitro células epiteliais primárias, para diagnosticar câncer de próstata, para selecionar um tratamento para um indivíduo tendo um câncer/tumor de próstata, linhagem de célula, e, modelo animal |
| GB201118876D0 (en) | 2011-11-01 | 2011-12-14 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| AU2013262977A1 (en) | 2012-05-14 | 2015-01-22 | Prostagene, Llc | Using modulators of CCR5 for treating cancer |
| WO2016094011A1 (en) * | 2014-12-11 | 2016-06-16 | Merck Sharp & Dohme Corp. | Crystal forms of a ccr5 antagonist |
| US12459808B2 (en) | 2021-09-13 | 2025-11-04 | Kabushiki Kaisha Toshiba | Sensor |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6391865B1 (en) * | 1999-05-04 | 2002-05-21 | Schering Corporation | Piperazine derivatives useful as CCR5 antagonists |
| CA2371583C (en) * | 1999-05-04 | 2005-09-13 | Schering Corporation | Piperazine derivatives useful as ccr5 antagonists |
| EP1373206B1 (en) * | 2001-03-29 | 2008-12-24 | Schering Corporation | Aryl oxime-piperazines useful as ccr5 antagonists |
-
2005
- 2005-10-21 US US11/255,643 patent/US7825121B2/en not_active Expired - Fee Related
-
2006
- 2006-10-18 KR KR1020087011479A patent/KR20080058486A/ko not_active Withdrawn
- 2006-10-18 CA CA002626565A patent/CA2626565A1/en not_active Abandoned
- 2006-10-18 AU AU2006306491A patent/AU2006306491B2/en not_active Ceased
- 2006-10-18 CN CNA2006800462485A patent/CN101326178A/zh active Pending
- 2006-10-18 BR BRPI0617731-0A patent/BRPI0617731A2/pt not_active IP Right Cessation
- 2006-10-18 JP JP2008536749A patent/JP2009512705A/ja active Pending
- 2006-10-18 WO PCT/US2006/040636 patent/WO2007050375A2/en not_active Ceased
- 2006-10-18 EP EP06826151.0A patent/EP1951708B1/en active Active
- 2006-10-18 RU RU2008119652/04A patent/RU2008119652A/ru not_active Application Discontinuation
- 2006-10-19 PE PE2006001267A patent/PE20070711A1/es not_active Application Discontinuation
- 2006-10-19 AR ARP060104564A patent/AR058105A1/es not_active Application Discontinuation
- 2006-10-20 TW TW095138842A patent/TW200800234A/zh unknown
-
2008
- 2008-04-15 IL IL190902A patent/IL190902A0/en unknown
- 2008-04-17 EC EC2008008378A patent/ECSP088378A/es unknown
- 2008-04-18 ZA ZA200803454A patent/ZA200803454B/xx unknown
- 2008-05-20 NO NO20082297A patent/NO20082297L/no not_active Application Discontinuation
-
2012
- 2012-01-17 JP JP2012007201A patent/JP2012072195A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1104238C (zh) | 霉酚酸盐的包有肠溶衣的药物组合物 | |
| CN108042808B (zh) | 用于治疗中枢系统疾病的包含依匹哌唑或其盐和第二种药物的组合 | |
| JP5769763B2 (ja) | 治療用組成物およびその使用 | |
| CN109890808A (zh) | 用于预防性或治疗性治疗hiv病毒感染的治疗性化合物 | |
| TW201023858A (en) | Synergistic combinations of a macrocyclic inhibitor of HCV and a nucleoside | |
| EP1940364A2 (en) | Capsule formulation of pirfenidone and pharmaceutically acceptable excipients | |
| JP2002519434A5 (https=) | ||
| WO2012011917A1 (en) | Administration of rifalazil to immunocompromised patients | |
| TW200817052A (en) | Solid dosage form of olmesartan medoxomil and amlodipine | |
| JP2002502875A (ja) | 肝炎ウイルス感染症を処置するためのｎ−置換−１，５−ジデオキシ−１，５−イミノ−ｄ−グルシトール化合物の使用 | |
| CN106999462A (zh) | 包含选择性s1p1受体激动剂的药物组合物 | |
| JP2009512705A5 (https=) | ||
| JP5084736B2 (ja) | 肺高血圧を処置するためのジアリールウレア | |
| JP2023057082A (ja) | ゲムカベン、薬学的に許容されるその塩、その組成物、およびその使用方法 | |
| CN108367001A (zh) | 治疗丁型肝炎病毒感染 | |
| CA2577740A1 (en) | Method of enhancing absorptions of transmucosal administration formulations | |
| JP2009517411A5 (https=) | ||
| WO2012020301A3 (en) | Oral controlled release pharmaceutical compositions of blonanserin | |
| KR20190061027A (ko) | 비-알코올성 지방간 질환의 치료를 위한 약학 조성물 및 방법 | |
| WO2018115888A1 (en) | Novel formulations of aprepitant | |
| KR20180071276A (ko) | Hcv 치료를 위한 조합물 요법 투약법 | |
| KR20220125232A (ko) | Ahr 억제제 및 이의 용도 | |
| JP2008534592A5 (https=) | ||
| JP2022523668A (ja) | Ｍａｇｌ阻害剤による疾病の治療方法 | |
| WO2008005352A3 (en) | Solid dose formulations of a thrombin receptor antagonist |